What’s causing the GT Biopharma, Inc. (GTBP) stock to experience downfall?
GT Biopharma, Inc. (GTBP) has experienced a downfall of 5.91% in the aftermarket. However, the last trading session concluded at $3.72. Demonstration of Novel B7-H3
GT Biopharma, Inc. (GTBP) has experienced a downfall of 5.91% in the aftermarket. However, the last trading session concluded at $3.72. Demonstration of Novel B7-H3
Orbsat Corp. (OSAT) has seen a push of 7.26% in the aftermarket. However, the last trading session closed at $3.72 with a decrease of 4.86%.
Orion Group Holdings, Inc. (ORN) experienced a decrease of 6.88% in the aftermarket. However, the last trading session closed at $3.78 with an increase of
N-able, Inc. (NABL) experienced a decrease of 5.29% in the premarket today. However, the last trading session concluded at $11.35 with an increase of 0.53%.
Naked Brand Group Limited (NAKD) is one of the leading company manufacturing, retailing, and marketing men and women intimate apparel line. The company also sells
Chembio Diagnostics, Inc. (CEMI) is an innovative leading diagnostics company primarily aiming to develop and commercialize tests that are used for the immediate detection and
Pasithea Therapeutics Corp. (KTTA) is one of the leading biopharmaceutical companies mainly engaged in the development and research of therapies related to psychiatry and neurological
Arbutus Biopharma Corporation (ABUS) is one of the leading biopharmaceutical companies focusing on the discovery, development, and commercialization of candidate products related to patients infected
Eloxx Pharmaceuticals, Inc. (ELOX) is a leading biopharmaceutical company aimed at developing innovative Ribosome Modulating Agents (RMAs). These RMAs are developed for the treatment of
Rockwell Medical, Inc. (RMTI) is a leading commercia-stage biopharmaceutical company. The company develops and commercializes next generation Ferric Pyrophosphate Citrate which is mainly used for
2022 ©All rights reserved! CatchingNews.com